Limitation On Future Patent Protection For Biosimilars?

Law360, New York (August 9, 2012, 1:36 PM EDT) -- On Aug. 3, 2012, the U.S. Court of Appeals for the Federal Circuit issued an opinion vacating a preliminary injunction that had been granted by the U.S. District Court for the District of Massachusetts to Momenta Pharmaceuticals Inc. and Sandoz Inc. (collectively, "Momenta"). See Momenta Pharmaceuticals Inc., et al. v. Amphastar Pharmaceuticals Inc., et al., Nos. 2012-1062, ‑1103, -1104 (Fed. Cir. Aug. 3, 2012).[1]

Momenta — the sole marketer in the United States of a generic version of Sanofi-Aventis U.S. LLC's branded drug Lovenox (enoxaparin) until...
To view the full article, register now.